UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address; COMMISSIONER FOR PATENTS

P O Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

28120 7590 02/27/2008

ROPES & GRAY LLP PATENT DOCKETING 39/41 ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624 EXAMINER

DEBERRY, REGINA M

ART UNIT PAPER NUMBER

1647 DATE MAILED: 02/27/2008

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/499,526 | 02/10/2000 | Kuanghui Lu | CIBT-P01-058 | 1398 |

TITLE OF INVENTION: METHODS AND REAGENTS FOR TREATING GLUCOSE METABOLIC DISORDERS

| APPLN, TYPE | SMALL ENTITY | ISSUE FEE DUE | PUBLICATION FEE DUE | PREV. PAID ISSUE FEE | TOTAL FEE(8) DUE | DATE DUE |
|----------------|--------------|---------------|---------------------|----------------------|------------------|------------|
| nonprovisional | NO | \$1440 | \$0 | \$0 | \$1440 | 05/27/2008 |

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

| appropriate. All further indicated unless corrects maintenance fee notifica | correspondence includir ed below or directed oth | ng the Patent, advance on herwise in Block 1, by (a | rders and notification of r a) specifying a new corres | naintenance fees wi pondence address; | ill be mailed to the curren and/or (b) indicating a sep | t correspondence address a parate "FEE ADDRESS" fo | |
|--|--|---|---|---|--|--|--|
| CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) | | | | Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, mus have its own certificate of mailing or transmission. | | | |
| 28120 | 7590 02/27 | /2008 | THE CO | | ificate of Mailing or Tran | | |
| | KETING 39/41 TIONAL PLACE | | I he Stat addi tran | cabo cartify that this | e Eag(e) Transmittal is bair | g deposited with the United est class mail in an envelope above, or being facsimile date indicated below. | |
| BOSTON, MA | 02110-2624 | | | | | (Depositor's name) | |
| | | | | | | (Signature) | |
| | | | | | | (Date) | |
| APPLICATION NO. | FILING DATE | | FIRST NAMED INVENTOR | | ATTORNEY DOCKET NO. | CONFIRMATION NO. | |
| 09/499,526 | 02/10/2000 | • | Kuanghui Lu | CIBT-P01-058 | | 1398 | |
| | : METHODS AND REA | GENTS FOR TREATIN | IG GLUCOSE METABOL | | | | |
| APPLN. TYPE | SMALL ENTITY | ISSUE FEE DUE | PUBLICATION FEE DUE | PREV. PAID ISSUE | FEE TOTAL FEE(S) DUI | E DATE DUE | |
| nonprovisional | NO | \$1440 | \$0 | \$0 | \$1440 | 05/27/2008 | |
| EXAM | IINER | ART UNIT | CLASS-SUBCLASS |] | | | |
| DEBERRY, | | 1647 | 514-002000 | | | | |
| 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.563). Change of correspondence address (or Change of Correspondence Address form "FTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form FTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. | | | (1) the names of up to or agents OR, alternativ (2) the name of a singl registered attorney or a | name of a single firm (having as a member a d attorney or agent) and the names of up to red patent attorneys or agents. If no name is | | | |
| PLEASE NOTE: Uni recordation as set fort (A) NAME OF ASSI | less an assignee is ident h in 37 CFR 3.11. Comp GNEE | ified below, no assignee detion of this form is NO | (B) RESIDENCE: (CITY | atent. If an assigne assignment. and STATE OR Co | OUNTRY) | document has been filed for | |
| | | | - | | | | |
| 4a. The following fee(s) Issue Fee Publication Fee (N Advance Order - : | vo small entity discount p | | A check is enclosed. Payment by credit car | d. Form PTO-2038 | e the required fee(s), any d | | |
| | s SMALL ENTITY state | is. See 37 CFR 1.27. | | | L ENTITY status. See 37 C | | |
| NOTE: The Issue Fee an interest as shown by the | d Publication Fee (if req records of the United Sta | uired) will not be accepte tes Patent and Trademark | d from anyone other than t Office. | he applicant; a regis | tered attorney or agent; or | the assignee or other party in | |
| Authorized Signature | | | | Date | | | |
| Typed or printed nam | | | | Registration No | | | |
| This collection of inform an application. Confiden submitting the complete this form and/or suggesti Box 1450, Alexandria, V Alexandria, Virginia 223 | nation is required by 37 C tiality is governed by 35 d application form to the ions for reducing this but 'irginia 22313-1450. DC i13-1450. | FR 1.311. The informatic U.S.C. 122 and 37 CFR USPTO. Time will vary den, should be sent to the ONOT SEND FEES OR | on is required to obtain or r 1.14. This collection is est depending upon the indiv e Chief Information Office COMPLETED FORMS TO | etain a benefit by th imated to take 12 m idual case. Any cor rr, U.S. Patent and 1 D THIS ADDRESS. | e public which is to file (ar ninutes to complete, includi mments on the amount of t frademark Office, U.S. De SEND TO: Commissioner | nd by the USPTO to process, ng gathering, preparing, and ime you require to complete partment of Commerce, P.O. for Patents, P.O. Box 1450 | |

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

s: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 02/27/2008

| APPLICATION N | 0. | FILING DATE FIRST NAMED INVENTOR | | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|------------------------|--|----------------------------------|-------------|---------------------|------------------|
| 09/499,526 | | 02/10/2000 | Kuanghui Lu | CIBT-P01-058 1398 | |
| 28120 | 7590 | 02/27/2008 | | EXAMINER | |
| ROPES & C | ROPES & GRAY LLP | | | DEBERRY, REGINA M | |
| PATENT DOCKETING 39/41 | | | ART UNIT | PAPER NUMBER | |
| | ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624 | | | 1647 | |

Determination of Patent Term Extension under 35 U.S.C. 154 (b)

(application filed after June 7, 1995 but prior to May 29, 2000)

The Patent Term Extension is 0 day(s). Any patent to issue from the above-identified application will include an indication of the 0 day extension on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Extension is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Application No. Applicant(s) 09/499 526 LU ET AL. Notice of Allowability Framiner Art Unit REGINA M DEBERRY 1647 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--All claims being allowable. PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. This communication is responsive to 10/12/07. 2. X The allowed claim(s) is/are 13,15-21,23,28-33,39,45,46,50,53,54,57-60,76-78,85,87-94,97,98,100-102,104-112,116-123,125-130 (renumbered as 1-4, 6,7,9,10,15-17,25,27,26,28,30-32,11,5,8,12,13,18-20,14,29,21,33-35,40-55. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). b) ☐ Some* c) ☐ None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. _____. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: . Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. Notice of References Cited (PTO-892) 5. Notice of Informal Patent Application Notice of Draftperson's Patent Drawing Review (PTO-948) Interview Summary (PTO-413). Paper No./Mail Date Information Disclosure Statements (PTO/SB/08). 7. X Examiner's Amendment/Comment

/Marianne P. Allen/ Primary Examiner, Art Unit 1647

9. ☐ Other .

8. T Examiner's Statement of Reasons for Allowance

Paper No./Mail Date 10/07, 2/08
4. Examiner's Comment Regarding Requirement for Decosit

of Biological Material

(claim renumbering continued from above: 22-24,36-39,56-65, respectively).

Application/Control Number: 09/499,526

Art Unit: 1647

EXAMINER'S AMENDMENT/COMMENT

An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's amendment was given by David Halstead via phone message on 2/04/08 and on 2/12/08.

The application has been amended as follows:

Please cancel claims 96 and 103.

In claims 13, 21 and 23 (lines 4-5 for all) and claims 33, 45 and 93 (lines 5-6 for all) and claim 130, lines 5-7:

Please change "wherein said PYY agonist comprises an amino acid sequence having a sequence identical to a peptide encoded by a nucleic acid sequence" to "wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence".

In claim 94, lines 6-7, and claim 102, lines 5-6:

Please change "wherein said PYY agonist comprises a polypeptide at least 70% identical with SEQ ID NO:3" to "wherein said PYY agonist comprises a polypeptide at least 80% identical with SEQ ID NO:3".

In claims 87, 88, and 89 (line 3 for all) and claims 90, 91, and 92 (line 4 for all):

Please change "an amount of a PYY of SEQ ID NO:2" to "an amount of a PYY comprising the amino acid sequence of SEQ ID NO:2".

Application/Control Number: 09/499,526

Art Unit: 1647

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance." Any inquiry concerning this communication or earlier communications from the examiner should be directed to REGINA M. DEBERRY whose telephone number is (571)272-0882. The examiner can normally be reached on 9:00 a.m.-6:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Marianne P. Allen/ Primary Examiner, Art Unit 1647

RMD 2/8/08